CINCINNATI, April 25 /PRNewswire-FirstCall/ -- Kendle , a leading global full-service clinical research organization (CRO), today announced it has completed its acquisition of Latin America CRO International Clinical Research Limited (IC-Research) and related companies, further strengthening its global clinical development capabilities in the Phase II-IV arena through new operations in Argentina, Brazil, Chile and Colombia. The move builds on the company’s strong base of operations in Mexico and Peru, with Kendle now offering coverage across more Latin American countries than any other CRO. The company’s offices in six major countries represent 80 percent of the region’s population, providing Kendle customers with significantly expanded access to one of the most important ascending regions for clinical research. Kendle announced its agreement to acquire IC-Research March 9.
(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO)
Kendle acquired the IC-Research business for an undisclosed cash amount. Specific terms of the agreement were not disclosed. The new locations are part of Kendle’s global network and report to Dennis Hurley, DrSc, Vice President, Global Clinical Development - Latin America. The acquisition is the culmination of an ongoing successful relationship between Kendle and IC- Research, in which the two companies have worked together in recent years on drug development programs in Latin America.
Kendle’s global clinical development business is organized in five regions - North America, Europe, Asia/Pacific, Latin America and Africa - to meet customer needs. The company’s focus is on strategic business expansion in high-growth regions to deliver global trials for its biopharmaceutical customers.
About Kendle
Kendle International Inc. is among the world’s leading global clinical research organizations. We deliver innovative and robust clinical development solutions - from first-in-human studies through market launch and surveillance - to help the world’s biopharmaceutical companies maximize product life cycles and grow market share. Our global clinical development business is focused on five regions - North America, Europe, Asia/Pacific, Latin America and Africa - to meet customer needs. With the expertise of our associates worldwide, Kendle has conducted clinical trials or provided regulatory, pharmacovigilance and validation services in 70 countries. Additional information and investor kits are available upon request from Kendle, 1200 Carew Tower, 441 Vine Street, Cincinnati, OH 45202 or from the Company’s Web site at http://www.kendle.com.
Information provided herein, which is not historical information, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements are based largely on management’s expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors and industry consolidation, outsourcing trends in the pharmaceutical and biotechnology industries, the company’s ability to manage growth and to continue to attract and retain qualified personnel, the company’s ability to integrate the newly acquired businesses, the fixed price nature of contracts or the loss of large contracts, cancellation or delay of contracts, the progress of ongoing contracts, the ability to maintain existing customer relationships or enter into new ones, cost overruns, the company’s sales cycle, the effects of exchange rate fluctuations, and other factors described in the company’s filings with the Securities and Exchange Commission, including Quarterly Reports on Form 10-Q and the Annual Report on Form 10-K. All information in this release is current as of April 25, 2006. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company’s expectations.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comKendle International Inc.
CONTACT: Investors, Patty Frank, +1-513-763-1992, or Media, Lori Dorer,+1-513-345-1685, both of Kendle International Inc.
Web site: http://www.kendle.com/
